Core Viewpoint - Palisade Bio, Inc. has decided to cancel its special meeting of stockholders originally scheduled for October 10, 2025, due to the lack of a required quorum [1][2]. Group 1: Special Meeting Details - The special meeting was previously adjourned to September 26, 2025, but was adjourned again without any business being conducted due to insufficient proxies to form a quorum [2]. - The company has not received the necessary proxies to constitute a quorum and has withdrawn the proposals set forth in the definitive proxy statement filed with the U.S. Securities and Exchange Commission on August 18, 2025 [2]. Group 2: Company Overview - Palisade Bio is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for patients with autoimmune, inflammatory, and fibrotic diseases [3]. - The company aims to transform the treatment landscape through a targeted approach with its novel therapeutics [3].

Core Viewpoint - Palisade Bio, Inc. has announced a public offering of 171,440,559 shares of its common stock at a price of $0.70 per share, aiming to raise approximately $120 million in gross proceeds before expenses [1][3]. Group 1: Offering Details - The offering includes a 45-day option for underwriters to purchase an additional 25,714,285 shares at the public offering price [2]. - The expected closing date for the offering is around October 2, 2025, pending customary closing conditions [3]. - A registration statement related to the offering was declared effective by the SEC on September 30, 2025, with an additional statement filed on October 1, 2025 [4]. Group 2: Company Overview - Palisade Bio is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for autoimmune, inflammatory, and fibrotic diseases [6]. - The company aims to transform the treatment landscape through a targeted approach with its therapeutics [6].

Core Viewpoint - Palisade Bio, Inc. has entered into an agreement with accredited investors to exercise existing warrants for the purchase of up to 4,318,905 shares of common stock at a reduced exercise price, generating approximately $3.9 million in gross proceeds for the company [1][2]. Group 1: Existing Warrants and Financial Details - The existing warrants were issued at adjusted exercise prices of $1.40 and will be exercised at a reduced price of $0.9047 per share [1]. - The gross proceeds from the exercise of the existing warrants are expected to be approximately $3.9 million before deducting fees and expenses [2]. - The company intends to use the net proceeds from the offering for working capital and general corporate purposes [4]. Group 2: Replacement Warrants - In exchange for the immediate exercise of existing warrants, holders will receive new unregistered replacement warrants to purchase up to 8,637,810 shares of common stock at an exercise price of $0.9047 per share, with a term of five years from shareholder approval [3]. - The replacement warrants are offered in a private placement and have not been registered under the Securities Act [5]. Group 3: Company Overview - Palisade Bio is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for patients with autoimmune, inflammatory, and fibrotic diseases [7].